RCDT.F Stock Overview
Engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Recordati Industria Chimica e Farmaceutica S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €52.25 |
| 52 Week High | €52.25 |
| 52 Week Low | €51.60 |
| Beta | 0.40 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -18.31% |
| 5 Year Change | n/a |
| Change since IPO | 546.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| RCDT.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.2% |
| 1Y | n/a | 9.9% | 31.6% |
Return vs Industry: Insufficient data to determine how RCDT.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RCDT.F performed against the US Market.
Price Volatility
| RCDT.F volatility | |
|---|---|
| RCDT.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RCDT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RCDT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 4,455 | Rob Koremans | www.recordati.com |
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.
Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary
| RCDT.F fundamental statistics | |
|---|---|
| Market cap | US$11.95b |
| Earnings (TTM) | US$417.90m |
| Revenue (TTM) | US$2.40b |
28.6x
P/E Ratio5.0x
P/S RatioIs RCDT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCDT.F income statement (TTM) | |
|---|---|
| Revenue | €2.22b |
| Cost of Revenue | €672.69m |
| Gross Profit | €1.55b |
| Other Expenses | €1.16b |
| Earnings | €387.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | 1.89 |
| Gross Margin | 69.75% |
| Net Profit Margin | 17.40% |
| Debt/Equity Ratio | 91.1% |
How did RCDT.F perform over the long term?
See historical performance and comparison